Analysts expect Burning Rock Biotech Ltd to report revenue of 42.14 M for Q2 25, against a range of 39.10 M to 45.18 M. The most recent reported quarter, Q1 25, came in at 15.65 M, a 60.5% miss against the 39.61 M consensus.
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 20.75 M | 20.16 M | 17.47 M | 17.05 M | 19.73 M | 18.64 M | 18.33 M | 18.06 M | 15.65 M | - | - | - | - | - | - | - |
| High Estimate | 20.66 M | 24.22 M | 27.95 M | 33.00 M | - | - | - | 24.24 M | 43.12 M | 45.18 M | 43.14 M | 54.86 M | 48.70 M | 40.69 M | 39.66 M | 40.11 M |
| Low Estimate | 19.08 M | 21.10 M | 23.02 M | 30.30 M | - | - | - | 21.84 M | 36.10 M | 39.10 M | 38.40 M | 47.61 M | 40.21 M | 36.41 M | 35.07 M | 34.72 M |
| Consensus Estimate | 19.87 M | 22.66 M | 25.48 M | 31.65 M | - | - | - | 23.04 M | 39.61 M | 42.14 M | 40.77 M | 51.24 M | 44.46 M | 38.55 M | 37.37 M | 37.41 M |
Analysts expect Burning Rock Biotech Ltd to report earnings per share of -0.62 for Q2 25, against a range of -0.68 to -0.56. The most recent reported quarter, Q1 25, came in at -0.03, a 95.4% beat against the -0.62 consensus.
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.63 | -1.76 | -2.34 | -2.23 | -0.25 | -0.14 | -0.05 | -0.02 | -0.03 | - | - | - | - | - | - | - |
| High Estimate | -1.83 | -1.61 | -1.62 | -1.63 | -1.48 | -1.48 | -1.32 | -1.23 | -0.60 | -0.56 | -0.67 | -1.82 | 1.16 | 1.36 | 1.41 | -0.32 |
| Low Estimate | -2.07 | -1.93 | -1.78 | -1.91 | -1.62 | -1.66 | -1.58 | -1.41 | -0.64 | -0.68 | -0.73 | -1.96 | 1.08 | 1.22 | 1.25 | -0.38 |
| Consensus Estimate | -1.95 | -1.77 | -1.70 | -1.77 | -1.55 | -1.57 | -1.45 | -1.32 | -0.62 | -0.62 | -0.70 | -1.89 | 1.12 | 1.29 | 1.33 | -0.35 |